|
A Phase 1 Vaccine Trial for Patients with Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Summary
The purpose of this study is to determine the safety and ability of DPX-Survivac, an investigational vaccine, in combination with low dose cyclophosphamide to enhance the immune system and may produce an anti-tumor immune response. It is possible that this immune response will in turn result in some therapeutic anti-cancer activity.
Description
DPX-Survivac is a therapeutic vaccine that teaches your own immune system to target cancer cells. This trial involves three subcutaneous vaccine injections 21 days apart, given in conjunction with or without oral cyclophoshamide. After completing the three vaccine injections, you will be followed by your study doctor for 6 months.
Inclusion/exclusion
To be eligible for this study, patients must meet several criteria, including but not limited to the following: Must be over 18 years old with stage IIc-IV ovarian, fallopian tube or peritoneal cancer Must have either stable disease after completion of first-line chemotherapy for recurrent disease or must have completed up to 8 cycles of chemotherapy after initial debulking surgery with evidence of complete or partial disease response. Must not have had or be recieving consolidation chemotherapy.
Principal Investigator
Jeannine Villella, D.O.
Department
Gynecology/Oncology
Email
jlbrown@winthrop.org
Other Contact
For more information please contact Jennifer Brown, Research Coordinator, at 516-663-3115.
|
